Singapore, April 17 -- Japanese pharma behemoth Shionogi & Co. has announced that its group company Taiwan Shionogi has received approval of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment and postexposure prophylaxis for influenza virus infection for paediatrics aged 5 to = 12 years of age for treating influenza A or B virus acute infection and the postexposure prophylaxis of influenza in Taiwan. The newly approved indication extends the option for treating and preventing influenza virus infections to children aged 5 to 20 kg, offering a new choice for managing influenza. Xofluza is a first-in-class, single-dose oral medicine with an innovative mechanism of action that has demonstrated effi...